Inhibition of p70 Ribosomal S6 Kinase (S6K1) Reduces Cortical Blood Flow in a Rat Model of Autism-Tuberous Sclerosis.
Autism spectrum disorders
Cerebral blood flow
PF-4708671
Tuberous sclerosis complex
p70 ribosomal S6 kinase
Journal
Neuromolecular medicine
ISSN: 1559-1174
Titre abrégé: Neuromolecular Med
Pays: United States
ID NLM: 101135365
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
04
01
2024
accepted:
04
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
The manifestations of tuberous sclerosis complex (TSC) in humans include epilepsy, autism spectrum disorders (ASD) and intellectual disability. Previous studies suggested the linkage of TSC to altered cerebral blood flow and metabolic dysfunction. We previously reported a significant elevation in cerebral blood flow in an animal model of TSC and autism of young Eker rats. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin could restore normal oxygen consumption and cerebral blood flow. In this study, we investigated whether inhibiting a component of the mTOR signaling pathway, p70 ribosomal S6 kinase (S6K1), would yield comparable effects. Control Long Evans and Eker rats were divided into vehicle and PF-4708671 (S6K1 inhibitor, 75 mg/kg for 1 h) treated groups. Cerebral regional blood flow (
Identifiants
pubmed: 38570425
doi: 10.1007/s12017-024-08780-7
pii: 10.1007/s12017-024-08780-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Subventions
Organisme : Rutgers University Foundation
ID : #21277
Informations de copyright
© 2024. The Author(s).
Références
Aryal, S., Longo, F., & Klann, E. (2021). Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice. Proceedings of the National Academy of Sciences of the United States of America, 118(18), e2001681118. https://doi.org/10.1073/pnas.2001681118
doi: 10.1073/pnas.2001681118
pubmed: 33906942
pmcid: 8106352
Bassetti, D., Luhmann, H. J., & Kirischuk, S. (2021). Effects of mutations in TSC genes on neurodevelopment and synaptic transmission. International Journal of Molecular Sciences, 22(14), 7273. https://doi.org/10.3390/ijms22147273
doi: 10.3390/ijms22147273
pubmed: 34298906
pmcid: 8305053
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011). Rapamycin passes the torch: A new generation of mTOR inhibitors. Nature Reviews Drug Discovery, 10(11), 868–880. https://doi.org/10.1038/nrd3531
doi: 10.1038/nrd3531
pubmed: 22037041
Bhattacharya, A., Mamcarz, M., Mullins, C., Choudhury, A., Boyle, R. G., Smith, D. G., Walker, D. W., & Klann, E. (2016). Targeting translation control with p70 S6 kinase 1 inhibitors to reverse phenotypes in fragile X syndrome mice. Neuropsychopharmacology, 41(8), 1991–2000. https://doi.org/10.1038/npp.2015.369
doi: 10.1038/npp.2015.369
pubmed: 26708105
pmcid: 4908636
Bombardieri, R., Pinci, M., Moavero, R., Cerminara, C., & Curatolo, P. (2010). Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. European Journal of Paediatric Neurology, 14(2), 146–149. https://doi.org/10.1016/j.ejpn.2009.03.003
doi: 10.1016/j.ejpn.2009.03.003
pubmed: 19369101
Cavalheiro, S., da Costa, M. D. S., & Richtmann, R. (2021). Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: A case report. Child’s Nervous System, 37(12), 3897–3899. https://doi.org/10.1007/s00381-021-05218-4
doi: 10.1007/s00381-021-05218-4
pubmed: 34008055
Chi, O. Z., Wu, C.-C., Liu, X., Rah, K. H., Jacinto, E., & Weiss, H. R. (2015). Restoration of normal cerebral oxygen consumption with rapamycin treatment in a rat model of autism-tuberous sclerosis. Neuromolecular Medicine, 17(3), 305–313. https://doi.org/10.1007/s12017-015-8359-5
doi: 10.1007/s12017-015-8359-5
pubmed: 26048361
pmcid: 4888058
Curatolo, P., Scheper, M., Emberti Gialloreti, L., Specchio, N., & Aronica, E. (2023). Is tuberous sclerosis complex-associated autism a preventable and treatable disorder? World Journal of Pediatrics. https://doi.org/10.1007/s12519-023-00762-2
doi: 10.1007/s12519-023-00762-2
pubmed: 37878130
Curatolo, P., Specchio, N., & Aronica, E. (2022). Advances in the genetics and neuropathology of tuberous sclerosis complex: Edging closer to targeted therapy. The Lancet Neurology, 21(9), 843–856. https://doi.org/10.1016/S1474-4422(22)00213-7
doi: 10.1016/S1474-4422(22)00213-7
pubmed: 35963265
Czapski, G. A., Babiec, L., Jęśko, H., Gąssowska-Dobrowolska, M., Cieślik, M., Matuszewska, M., Frontczak-Baniewicz, M., Zajdel, K., & Adamczyk, A. (2021). Synaptic alterations in a transgenic model of tuberous sclerosis complex: Relevance to autism spectrum disorders. International Journal of Molecular Sciences, 22(18), 10058. https://doi.org/10.3390/ijms221810058
doi: 10.3390/ijms221810058
pubmed: 34576223
pmcid: 8466868
de Vries, P. J. (2010). Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics, 7(3), 275–282. https://doi.org/10.1016/j.nurt.2010.05.001
doi: 10.1016/j.nurt.2010.05.001
pubmed: 20643380
pmcid: 5084231
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008). Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature Medicine, 14(8), 843–848. https://doi.org/10.1038/nm1788
doi: 10.1038/nm1788
pubmed: 18568033
pmcid: 2664098
Franz, D. N., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., & French, J. A. (2021). Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. Epilepsia, 62(12), 3029–3041. https://doi.org/10.1111/epi.17099
doi: 10.1111/epi.17099
pubmed: 34693520
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., & Franz, D. N. (2016). Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study. The Lancet (London, England), 388(10056), 2153–2163. https://doi.org/10.1016/S0140-6736(16)31419-2
doi: 10.1016/S0140-6736(16)31419-2
pubmed: 27613521
Ganesan, H., Balasubramanian, V., Iyer, M., Venugopal, A., Subramaniam, M. D., Cho, S.-G., & Vellingiri, B. (2019). mTOR signalling pathway: A root cause for idiopathic autism? BMB Reports, 52(7), 424–433. https://doi.org/10.5483/BMBRep.2019.52.7.137
doi: 10.5483/BMBRep.2019.52.7.137
pubmed: 31186084
pmcid: 6675248
Ganesh, S. K., & Subathra Devi, C. (2023). Molecular and therapeutic insights of rapamycin: A multi-faceted drug from Streptomyces hygroscopicus. Molecular Biology Reports, 50(4), 3815–3833. https://doi.org/10.1007/s11033-023-08283-x
doi: 10.1007/s11033-023-08283-x
pubmed: 36696023
pmcid: 9875782
Gkogkas, C. G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D. B., & Sonenberg, N. (2013). Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature, 493(7432), 371–377. https://doi.org/10.1038/nature11628
doi: 10.1038/nature11628
pubmed: 23172145
Habib, S. L. (2010). Tuberous sclerosis complex and DNA repair. Advances in Experimental Medicine and Biology, 685, 84–94. https://doi.org/10.1007/978-1-4419-6448-9_8
doi: 10.1007/978-1-4419-6448-9_8
pubmed: 20687497
Harrington, L. S., Findlay, G. M., & Lamb, R. F. (2005). Restraining PI3K: MTOR signalling goes back to the membrane. Trends in Biochemical Sciences, 30(1), 35–42. https://doi.org/10.1016/j.tibs.2004.11.003
doi: 10.1016/j.tibs.2004.11.003
pubmed: 15653324
Hayashi, I., Aoki, Y., Ushikubo, H., Asano, D., Mori, A., Sakamoto, K., Nakahara, T., & Ishii, K. (2016). Protective effects of PF-4708671 against N-methyl-d-aspartic acid-induced retinal damage in rats. Fundamental & Clinical Pharmacology, 30(6), 529–536. https://doi.org/10.1111/fcp.12216
doi: 10.1111/fcp.12216
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016). Tuberous sclerosis complex. Nature Reviews Disease Primers, 2, 16035. https://doi.org/10.1038/nrdp.2016.35
doi: 10.1038/nrdp.2016.35
pubmed: 27226234
Hosking, S. L., Roff Hilton, E. J., Embleton, S. J., & Gupta, A. K. (2003). Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. The British Journal of Ophthalmology, 87(1), 96–100. https://doi.org/10.1136/bjo.87.1.96
doi: 10.1136/bjo.87.1.96
pubmed: 12488271
pmcid: 1771473
Huang, J., & Manning, B. D. (2008). The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. The Biochemical Journal, 412(2), 179–190. https://doi.org/10.1042/BJ20080281
doi: 10.1042/BJ20080281
pubmed: 18466115
Kelleher, R. J., & Bear, M. F. (2008). The autistic neuron: Troubled translation? Cell, 135(3), 401–406. https://doi.org/10.1016/j.cell.2008.10.017
doi: 10.1016/j.cell.2008.10.017
pubmed: 18984149
Koike-Kumagai, M., Fujimoto, M., & Wataya-Kaneda, M. (2022). Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. Neuropharmacology, 218, 109203. https://doi.org/10.1016/j.neuropharm.2022.109203
doi: 10.1016/j.neuropharm.2022.109203
pubmed: 35931213
Krueger, D. A., Capal, J. K., Curatolo, P., Devinsky, O., Ess, K., Tzadok, M., … & TSCure Research Group. (2018). Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 22(6), 1066–1073. https://doi.org/10.1016/j.ejpn.2018.06.007
doi: 10.1016/j.ejpn.2018.06.007
Kútna, V., Uttl, L., Waltereit, R., Krištofiková, Z., Kaping, D., Petrásek, T., Hoschl, C., & Ovsepian, S. V. (2020). Tuberous sclerosis (tsc2+/-) model Eker rats reveals extensive neuronal loss with microglial invasion and vascular remodeling related to brain neoplasia. Neurotherapeutics, 17(1), 329–339. https://doi.org/10.1007/s13311-019-00812-6
doi: 10.1007/s13311-019-00812-6
pubmed: 31820275
Li, J., Kim, S. G., & Blenis, J. (2014). Rapamycin: One drug, many effects. Cell Metabolism, 19(3), 373–379. https://doi.org/10.1016/j.cmet.2014.01.001
doi: 10.1016/j.cmet.2014.01.001
pubmed: 24508508
pmcid: 3972801
Magaway, C., Kim, E., & Jacinto, E. (2019). Targeting mTOR and metabolism in cancer: Lessons and innovations. Cells, 8(12), 1584. https://doi.org/10.3390/cells8121584
doi: 10.3390/cells8121584
pubmed: 31817676
pmcid: 6952948
Mizuguchi, M., Ohsawa, M., Kashii, H., & Sato, A. (2021). Brain symptoms of tuberous sclerosis complex: Pathogenesis and treatment. International Journal of Molecular Sciences, 22(13), 6677. https://doi.org/10.3390/ijms22136677
doi: 10.3390/ijms22136677
pubmed: 34206526
pmcid: 8268912
Oh, W. J., & Jacinto, E. (2011). mTOR complex 2 signaling and functions. Cell Cycle, 10(14), 2305–2316. https://doi.org/10.4161/cc.10.14.16586
doi: 10.4161/cc.10.14.16586
pubmed: 21670596
pmcid: 3322468
Pagani, M., Barsotti, N., Bertero, A., Trakoshis, S., Ulysse, L., Locarno, A., & Gozzi, A. (2021). mTOR-related synaptic pathology causes autism spectrum disorder-associated functional hyperconnectivity. Nature Communications, 12(1), 6084. https://doi.org/10.1038/s41467-021-26131-z
doi: 10.1038/s41467-021-26131-z
pubmed: 34667149
pmcid: 8526836
Pearce, L. R., Alton, G. R., Richter, D. T., Kath, J. C., Lingardo, L., Chapman, J., Hwang, C., & Alessi, D. R. (2010). Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). The Biochemical Journal, 431(2), 245–255. https://doi.org/10.1042/BJ20101024
doi: 10.1042/BJ20101024
pubmed: 20704563
Peters, J. M., Prohl, A., Kapur, K., Nath, A., Scherrer, B., Clancy, S., Prabhu, S. P., Sahin, M., Franz, D. N., Warfield, S. K., & Krueger, D. A. (2019). Longitudinal effects of everolimus on white matter diffusion in tuberous sclerosis complex. Pediatric Neurology, 90, 24–30. https://doi.org/10.1016/j.pediatrneurol.2018.10.005
doi: 10.1016/j.pediatrneurol.2018.10.005
pubmed: 30424962
Peters, J. M., Taquet, M., Prohl, A. K., Scherrer, B., Van Eeghen, A. M., Prabhu, S. P., Sahin, M., & Warfield, S. K. (2013). Diffusion tensor imaging and related techniques in tuberous sclerosis complex: Review and future directions. Future Neurology, 8(5), 583–597. https://doi.org/10.2217/fnl.13.37
doi: 10.2217/fnl.13.37
pubmed: 24489482
pmcid: 3904372
Rubenstein, J. L. R., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes, Brain, and Behavior, 2(5), 255–267. https://doi.org/10.1034/j.1601-183x.2003.00037.x
doi: 10.1034/j.1601-183x.2003.00037.x
pubmed: 14606691
Rutten, C., Fillon, L., Kuchenbuch, M., Saitovitch, A., Boisgontier, J., Chemaly, N., & Boddaert, N. (2023). The longitudinal evolution of cerebral blood flow in children with tuberous sclerosis assessed by arterial spin labeling magnetic resonance imaging may be related to cognitive performance. European Radiology, 33(1), 196–206. https://doi.org/10.1007/s00330-022-09036-3
doi: 10.1007/s00330-022-09036-3
pubmed: 36066730
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell, 22(2), 159–168. https://doi.org/10.1016/j.molcel.2006.03.029
doi: 10.1016/j.molcel.2006.03.029
pubmed: 16603397
Schneider, M., de Vries, P. J., Schönig, K., Rößner, V., & Waltereit, R. (2017). mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus. European Archives of Psychiatry and Clinical Neuroscience, 267(5), 455–463. https://doi.org/10.1007/s00406-016-0703-8
doi: 10.1007/s00406-016-0703-8
pubmed: 27263037
Sharma, A., & Mehan, S. (2021). Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochemistry International, 147, 105067. https://doi.org/10.1016/j.neuint.2021.105067
doi: 10.1016/j.neuint.2021.105067
pubmed: 33992742
Spanaki, M. V., Siegel, H., Kopylev, L., Fazilat, S., Dean, A., Liow, K., Ben-Menachem, E., Gaillard, W. D., & Theodore, W. H. (1999). The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology, 53(7), 1518–1522. https://doi.org/10.1212/wnl.53.7.1518
doi: 10.1212/wnl.53.7.1518
pubmed: 10534261
Specchio, N., Nabbout, R., Aronica, E., Auvin, S., Benvenuto, A., de Palma, L., & Curatolo, P. (2023). Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. European Journal of Paediatric Neurology, 47, 25–34. https://doi.org/10.1016/j.ejpn.2023.08.005
doi: 10.1016/j.ejpn.2023.08.005
pubmed: 37669572
Srivastava, I. N., Shperdheja, J., Baybis, M., Ferguson, T., & Crino, P. B. (2016). mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy. Neurobiology of Disease, 85, 144–154. https://doi.org/10.1016/j.nbd.2015.10.001
doi: 10.1016/j.nbd.2015.10.001
pubmed: 26459113
Szwed, A., Kim, E., & Jacinto, E. (2021). Regulation and metabolic functions of mTORC1 and mTORC2. Physiological Reviews, 101(3), 1371–1426. https://doi.org/10.1152/physrev.00026.2020
doi: 10.1152/physrev.00026.2020
pubmed: 33599151
pmcid: 8424549
Talos, D. M., Sun, H., Kosaras, B., Joseph, A., Folkerth, R. D., Poduri, A., Madsen, J. R., Black, P. M., & Jensen, F. E. (2012). Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Annals of Neurology, 71(4), 539–551. https://doi.org/10.1002/ana.22696
doi: 10.1002/ana.22696
pubmed: 22447678
pmcid: 3334406
Tavares, M. R., Pavan, I. C. B., Amaral, C. L., Meneguello, L., Luchessi, A. D., & Simabuco, F. M. (2015). The S6K protein family in health and disease. Life Sciences, 131, 1–10. https://doi.org/10.1016/j.lfs.2015.03.001
doi: 10.1016/j.lfs.2015.03.001
pubmed: 25818187
Tsai, P. T., Hull, C., Chu, Y., Greene-Colozzi, E., Sadowski, A. R., Leech, J. M., Steinberg, J., Crawley, J. N., Regehr, W. G., & Sahin, M. (2012). Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature, 488(7413), 647–651. https://doi.org/10.1038/nature11310
doi: 10.1038/nature11310
pubmed: 22763451
pmcid: 3615424
Waltereit, R., Japs, B., Schneider, M., de Vries, P. J., & Bartsch, D. (2011). Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats. Behavior Genetics, 41(3), 364–372. https://doi.org/10.1007/s10519-010-9399-0
doi: 10.1007/s10519-010-9399-0
pubmed: 20927644
Weiss, H. R., Liu, X., & Chi, O. Z. (2008). Cerebral O(2) consumption in young Eker rats, effects of GABA blockade: Implications for autism. International Journal of Developmental Neuroscience, 26(5), 517–521. https://doi.org/10.1016/j.ijdevneu.2008.01.002
doi: 10.1016/j.ijdevneu.2008.01.002
pubmed: 18282678
Weiss, H. R., Liu, X., Grewal, P., & Chi, O. Z. (2012). Reduced effect of stimulation of AMPA receptors on cerebral O
doi: 10.1016/j.neuropharm.2012.06.014
pubmed: 22722031
Weiss, H. R., Liu, X., Hunter, C., & Chi, O. Z. (2009). Effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor blockade on increased cerebral O(2) consumption in Eker rats. Brain Research, 1294, 138–143. https://doi.org/10.1016/j.brainres.2009.08.022
doi: 10.1016/j.brainres.2009.08.022
pubmed: 19686708
Weiss, H. R., Liu, X., Zhang, Q., & Chi, O. Z. (2007). Increased cerebral oxygen consumption in Eker rats and effects of N-methyl-D-aspartate blockade: Implications for autism. Journal of Neuroscience Research, 85(11), 2512–2517. https://doi.org/10.1002/jnr.21378
doi: 10.1002/jnr.21378
pubmed: 17549750
Wenzel, H. J., Patel, L. S., Robbins, C. A., Emmi, A., Yeung, R. S., & Schwartzkroin, P. A. (2004). Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Acta Neuropathologica, 108(2), 97–108. https://doi.org/10.1007/s00401-004-0865-8
doi: 10.1007/s00401-004-0865-8
pubmed: 15185103
Winden, K. D., Ebrahimi-Fakhari, D., & Sahin, M. (2018). Abnormal mTOR activation in autism. Annual Review of Neuroscience, 41, 1–23. https://doi.org/10.1146/annurev-neuro-080317-061747
doi: 10.1146/annurev-neuro-080317-061747
pubmed: 29490194
Zeng, L.-H., Xu, L., Gutmann, D. H., & Wong, M. (2008). Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Annals of Neurology, 63(4), 444–453. https://doi.org/10.1002/ana.21331
doi: 10.1002/ana.21331
pubmed: 18389497
pmcid: 3937593